ALLISON ZARTMAN: Open Payments
NPI 1598473464 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$774 in 48 payments from 13 companies in 2025. Trend: 2023 $476 · 2024 $344 · 2025 $774
Food & beverage: $774
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $142 |
| Vanda Pharmaceuticals Inc. | 10 | $139 |
| Neurocrine BioSciences, Inc. | 3 | $81 |
| Tris Pharma Inc | 4 | $73 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $67 |
| Corium, LLC | 4 | $54 |
| Alkermes, Inc. | 3 | $51 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
Products named: VRAYLAR, FANAPT, INGREZZA, CAPLYTA, Dyanavel XR, Azstarys, Auvelity, ARISTADA.
Industry payments across ID — which companies pay providers there.
